



(43) International Publication Date
3 April 2014 (03.04.2014)

(10) International Publication Number
WO 2014/048881 A1

(51) International Patent Classification:

A61K 45/06 (2006.01) *A61P 35/00* (2006.01)
A61K 31/4412 (2006.01) *A61P 35/04* (2006.01)
A61K 31/616 (2006.01)

(21) International Application Number:

PCT/EP2013/069735

(22) International Filing Date:

23 September 2013 (23.09.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

12185852.6 25 September 2012 (25.09.2012) EP

(71) Applicants: **BAYER PHARMA AKTIENGESELLSCHAFT** [DE/DE]; Müllerstr. 178, 13353 Berlin (DE).
BAYER AG [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors: **WEBER, Olaf**; Flehenberg 28, 42489 Wülfrath (DE). **ZIEGELBAUER, Karl**; Düppelstr. 2a, 42781 Haan (DE).

(74) Agent: **BIP PATENTS**; c/o Bayer Intellectual Property GmbH, Creative Campus Monheim, Alfred-Nobel-Str. 10, 40789 Monheim (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: COMBINATION OF REGORAFENIB AND ACETYLSALICYLIC ACID FOR TREATING CANCER

(57) Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.



WO 2014/048881 A1